Literature DB >> 21075303

Can antitumor immunity help to explain "oncogene addiction"?

Nicholas P Restifo1.   

Abstract

Entities:  

Year:  2010        PMID： 21075303      PMCID： PMC2999628          DOI： 10.1016/j.ccr.2010.11.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  10 in total

1.  Oct-3/4 is a dose-dependent oncogenic fate determinant.

Authors:  Sharon Gidekel; Galina Pizov; Yehudit Bergman; Eli Pikarsky
Journal:  Cancer Cell       Date:  2003-11       Impact factor: 31.743

2.  CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.

Authors:  Kavya Rakhra; Pavan Bachireddy; Tahera Zabuawala; Robert Zeiser; Liwen Xu; Andrew Kopelman; Alice C Fan; Qiwei Yang; Lior Braunstein; Erika Crosby; Sandra Ryeom; Dean W Felsher
Journal:  Cancer Cell       Date:  2010-10-28       Impact factor: 31.743

Review 3.  The concept of synthetic lethality in the context of anticancer therapy.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2005-09       Impact factor: 60.716

Review 4.  Adoptive immunotherapy for cancer: building on success.

Authors:  Luca Gattinoni; Daniel J Powell; Steven A Rosenberg; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2006-05       Impact factor: 53.106

5.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 6.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

7.  Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors:  Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal:  N Engl J Med       Date:  2010-08-26       Impact factor: 91.245

8.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

Review 9.  Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?

Authors:  Dean W Felsher
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 10.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486
  10 in total
  14 in total

Review 1.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 2.  Adoptive immunotherapy for cancer: harnessing the T cell response.

Authors:  Nicholas P Restifo; Mark E Dudley; Steven A Rosenberg
Journal:  Nat Rev Immunol       Date:  2012-03-22       Impact factor: 53.106

Review 3.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

4.  Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.

Authors:  David I Bellovin; Bikul Das; Dean W Felsher
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 5.  Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.

Authors:  P Bachireddy; K Rakhra; D W Felsher
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

Review 6.  MYC: Master Regulator of Immune Privilege.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Trends Immunol       Date:  2017-02-21       Impact factor: 16.687

Review 7.  MYC activation is a hallmark of cancer initiation and maintenance.

Authors:  Meital Gabay; Yulin Li; Dean W Felsher
Journal:  Cold Spring Harb Perspect Med       Date:  2014-06-02       Impact factor: 6.915

Review 8.  Noncanonical roles of the immune system in eliciting oncogene addiction.

Authors:  Stephanie C Casey; David I Bellovin; Dean W Felsher
Journal:  Curr Opin Immunol       Date:  2013-04-06       Impact factor: 7.486

Review 9.  Inactivation of MYC reverses tumorigenesis.

Authors:  Y Li; S C Casey; D W Felsher
Journal:  J Intern Med       Date:  2014-07       Impact factor: 8.989

Review 10.  Modulation of tumor tolerance in primary central nervous system malignancies.

Authors:  Theodore S Johnson; David H Munn; Bernard L Maria
Journal:  Clin Dev Immunol       Date:  2012-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.